Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
dsg3 CRISPR/Cas9 KO Plasmid (h): sc-401809
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- dsg3 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the dsg3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: dsg3 Antibody (5H10): sc-23912
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
dsg3 CRISPR/Cas9 KO Plasmid (h) | sc-401809 | 20 µg | $397.00 |
Overview
DSG3 encodes desmoglein-3, a desmosomal cadherin that mediates calcium-dependent cell–cell adhesion in stratified epithelia and supports tissue integrity under mechanical stress. dsg3 interacts with desmoplakin and plakoglobin to anchor intermediate filaments and coordinate junctional organization, linking desmosome assembly to cytoskeletal remodeling and epithelial differentiation programs. Through its role in adhesion-dependent signaling, DSG3 influences processes such as barrier formation, cell polarity, and collective migration. Altered DSG3 expression or autoantibody targeting of desmoglein-3 has been associated with epithelial fragility and blistering phenotypes, and dysregulated desmosomal components are frequently studied in epithelial tumor biology.
dsg3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the DSG3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the DSG3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the DSG3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish dsg3 protein expression.
This CRISPR knockout system enables efficient generation of DSG3-deficient cell models for investigation of dsg3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting DSG3 exon(s) critical for dsg3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple DSG3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by dsg3 CRISPR/Cas9 KO Plasmid (h) and dsg3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the DSG3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by dsg3 HDR Plasmid (h) and dsg3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by DSG3 homology arms to support homology-directed repair at defined DSG3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.